NCT07414446

Brief Summary

The goal of this clinical trial is to learn how well the SONAS ultrasound device can detect right-to-left shunts of adults with hereditary hemorrhagic telangiectasia (HHT) who are already scheduled for a contrast bubble echocardiogram (TTCE). The main questions it aims to answer are:

  1. 1.How accurately does SONAS detect right-to-left shunts compared to the standard TTCE test?
  2. 2.Can SONAS results help tell the difference between shunts in the heart and shunts in the lungs?

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 7, 2026

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

February 3, 2026

Completed
14 days until next milestone

First Posted

Study publicly available on registry

February 17, 2026

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

February 17, 2026

Status Verified

February 1, 2026

Enrollment Period

3 months

First QC Date

February 3, 2026

Last Update Submit

February 10, 2026

Conditions

Keywords

Hereditary Hemorrhagic TelangiectasisaPulmonary Arteriovenous MalformationRight-to-Left ShuntContrast EchocardiographyTranscranial UltrasoundMicrobubblesPatent Foramen OvaleCryptogenic Stroke

Outcome Measures

Primary Outcomes (2)

  • Capability of detecting Right-to-Left Shunts

    Device capability of detecting High Intensity Transient Signals (HITS) using SONAS in presence of RLS, as confirmed by reference method TTCE. SONAS output is expressed as maximum HITS Density Score (0-100%). TTCE outcome is assessed by RLS grade (0-3), maximum microbubble count in left ventricle, and corrected change in echo density.

    Periprocedurally

  • Diagnostic accuracy

    Diagnostic accuracy (sensitivity and specificity) of SONAS for detection of clinically significant RLS (≥grade 2 on TTCE) at different HITS Density Score thresholds.

    Periprocedurally

Secondary Outcomes (2)

  • Distinguishing intracardiac from pulmonary Right-to-Left Shunts

    Periprocedurally

  • Test-retest reliability of SONAS for HITS assessment

    Periprocedurally

Study Arms (1)

SONAS Ultrasound During Contrast Echocardiography

EXPERIMENTAL

This study has a single arm in which all participants undergo SONAS monitoring during a standard contrast echocardiogram (transthoracic contrast echocardiography). In this arm, adults with (possible) hereditary hemorrhagic telangiectasia or PFO who are already scheduled for a clinically indicated bubble echocardiogram have a headband with the SONAS ultrasound device examination. Agitated saline is injected into a vein as part of usual care, and the heart is imaged with echocardiography while SONAS simultaneously records ultrasound signals from the brain.

Device: Transcranial Ultrasound Device

Interventions

The intervention is the SONAS ultrasound device used during a routine bubble echocardiogram. A battery-powered unit connects to a headset with two ultrasound sensors placed in front of the ears. The device does not deliver contrast or drugs; it records ultrasound signals in the brain while standard agitated saline is injected and the heart is imaged. SONAS analyzes bubble-related signals and calculates a numeric score to evaluate right-to-left shunts without changing the usual echocardiography protocol.

Also known as: SONAS, Foqus
SONAS Ultrasound During Contrast Echocardiography

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years or older.
  • Suspected or confirmed hereditary hemorrhagic telangiectasia (HHT).
  • Incidentally: Patients who have experienced cryptogenic stroke

You may not qualify if:

  • Pregnancy or breastfeeding.
  • Known or suspected fracture(s) of the temporal / parietal skull bones, or with open skin injuries in the anatomical area of the temporal / parietal lobes.
  • Patients with known metal skull implants in the anatomical area of the temporal / parietal bones, or with anatomical formation of the head or ear tha may interfere with proper headset placement.
  • Patients with known allergies or reactions to parabens, which are present in the gel pad material of the applied part.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Antonius Hospital

Nieuwegein, Utrecht, 3435CM, Netherlands

RECRUITING

MeSH Terms

Conditions

Telangiectasia, Hereditary HemorrhagicForamen Ovale, PatentPulmonary Arteriovenous FistulasIschemic Stroke

Condition Hierarchy (Ancestors)

Hemostatic DisordersVascular DiseasesCardiovascular DiseasesTelangiectasisHemorrhagic DisordersHematologic DiseasesHemic and Lymphatic DiseasesVascular MalformationsCardiovascular AbnormalitiesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHeart Septal Defects, AtrialHeart Septal DefectsHeart Defects, CongenitalHeart DiseasesStrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Martijn C. Post, Professor

    St. Antonius Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Pier HJ van Veen, Medical Doctor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 3, 2026

First Posted

February 17, 2026

Study Start

January 7, 2026

Primary Completion

April 1, 2026

Study Completion

April 1, 2026

Last Updated

February 17, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

All anonymized Individual Patient Data that underlie results in the publication.

Shared Documents
STUDY PROTOCOL
Time Frame
Beginning 3 months and ending 2 years after the publication of results.
Access Criteria
Fellow researchers interested in doing a meta-analysis of data will be able to access the IPD and supporting information. There will be access to the Study Protocol and anonymized individual patient data. Access is possible by contacting the Central Contact Person or Principal Investigator of the study.

Locations